Session » (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0446

A Balancing Act: The Interplay Between Resilience and Frailty in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0467

A Machine Learning Classifier Leveraging Anti-RA33, Anti-PAD4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA

10:30AM-12:30PM: Abstract Number: 0455

Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 0443

Association between pan-immune-inflammation and synovitis as assessed by ultrasound in rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 0442

Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort

10:30AM-12:30PM: Abstract Number: 0431

Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0441

Charting the Course of Worsening: Utilizing Standard Outcomes to Define Worsening for Pathophysiological Insights into RA

10:30AM-12:30PM: Abstract Number: 0435

Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0449

Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life

10:30AM-12:30PM: Abstract Number: 0462

Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?

10:30AM-12:30PM: Abstract Number: 0469

Evaluating Large Language Models for Automated Joint Involvement Analysis in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0438

Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0447

Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases

10:30AM-12:30PM: Abstract Number: 0432

Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0445

GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0456

Impact of Rheumatoid Arthritis on mortality and other outcomes in Heart failure: A nationwide analysis.

10:30AM-12:30PM: Abstract Number: 0448

Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study

10:30AM-12:30PM: Abstract Number: 0433

In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022

10:30AM-12:30PM: Abstract Number: 0437

Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention

10:30AM-12:30PM: Abstract Number: 0444

Low Disease Activity: Good Enough?

10:30AM-12:30PM: Abstract Number: 0451

Menopause Status and Disease Activity in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0454

Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights

10:30AM-12:30PM: Abstract Number: 0439

Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort

10:30AM-12:30PM: Abstract Number: 0468

Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis (ERS-RA) in a nationwide multicenter Chinese cohort

10:30AM-12:30PM: Abstract Number: 0466

Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects

10:30AM-12:30PM: Abstract Number: 0457

Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening

10:30AM-12:30PM: Abstract Number: 0465

Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women

10:30AM-12:30PM: Abstract Number: 0430

Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD

10:30AM-12:30PM: Abstract Number: 0461

Right Diagnoses For the Wrong Reasons: Limitations of Current Large-Language Model based Agentic Frameworks for Screening of Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0459

Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0453

Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD

10:30AM-12:30PM: Abstract Number: 0463

Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 0464

Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty

10:30AM-12:30PM: Abstract Number: 0452

Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments

10:30AM-12:30PM: Abstract Number: 0434

The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice

10:30AM-12:30PM: Abstract Number: 0450

The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0460

The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0440

The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease

10:30AM-12:30PM: Abstract Number: 0458

TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0436

Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].